Testing a Handheld Brain Scanner and Blood Test for Suspected Stroke in India
Checks a handheld scanner plus a quick blood test in adults with suspected stroke.
Plain-language title generated from the registry record
Registry title: Glial Fibrillary Acidic Protein Testing and Handheld Near Infrared Spectroscopy Technology CEREBO in India.
Key facts
- Where
- Ludhiana and Puducherry, IndiaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07844109, who can take part
Where in India
- Christian Medical College and HospitalLudhiana, IndiaNo longer taking part
- Jawaharlal Institute of Postgraduate Medical Education and Research Puducherry JIPMERPuducherry, IndiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Christian Medical College and Hospital, Ludhiana, India
- Trial code
- NCT07844109
- Record updated
- 28 September 2026
- Original description
CEREBO is an ICMR award winning point-of-care (POC) adjunct CT scanning device for detecting brain hematomas in patients with head injury. The study aims to validate the diagnostic accuracy of the PREDICT Assessment Model (CEREBO-NIRS plus GFAP/D-Dimer POC Assay) in patients with suspected stroke. The study will be conducted as part of the Indian Council of Medical Research's National Health Research Priority (ICMR-NHRP) under the INDIA-EMS project using a two phase design.Read full original descriptionShow less
Prehospital Rapid Evaluation and Detection in Cerebrovascular Triage: A Multicenter Study of Glial Fibrillary Acidic Protein Point of Care Testing and Handheld Near Infrared Spectroscopy Technology CEREBO in India.
CEREBO is an ICMR award winning point-of-care (POC) adjunct CT scanning device for detecting brain hematomas in patients with head injury. The study aims to validate the diagnostic accuracy of the PREDICT Assessment Model (CEREBO-NIRS plus GFAP/D-Dimer POC Assay) in patients with suspected stroke. The study will be conducted as part of the Indian Council of Medical Research's National Health Research Priority (ICMR-NHRP) under the INDIA-EMS project using a two phase design.
PHASE I: Validation of a diagnostic accuracy and feasbility of PREDICT assessment model (a combined approach using GFAP/ D-dimer POC lateral flow assay plus CEREBO-NIRS technology).
Study Design: Prospective, Multicenter, Validation and Feasibility Study.
PHASE II: Pilot RCT to assess integration of the PREDICT assessment model into pre-hospital pathways.
Study Design: Pilot Randomized Controlled Trial (RCT) (Year 3-5)
Inclusion: Adult patients of any gender ≥18 years with clinically suspected stroke; Transported by ambulance or presenting directly to ED of participating hospitals; Time from symptom onset/ Lost known well time (within 24 hours); Consent provided by patient/ next of kin; Adult patients of any gender ≥18 years with clinically suspected stroke; Transported by ambulance to ED of participating hospitals; Time from symptom onset/ Last well known time (≤ 24 hours); NIHSS ≥ 5; Consent provided by patient/ next of kin.
Exclusion: Patients with known pre-existing neurological conditions that may confound diagnosis (Concurrent traumatic brain injury, recent TBI in last 3months, IS/ICH in last 3 months, Diagnosis of brain tumour/SOL); Patients with known pre-existing neurological conditions that may confound diagnosis (Concurrent traumatic brain injury, recent TBI in last 3months, IS/ ICH in last 3 months, Diagnosis of brain tumour/ SOL); Patients with known medical condition with estimated life expectancy ≤ 3 months; Patients with known medical condition with estimated life expectancy ≤ 3 months; Those refusing consent; Phase 2; Those refusing consent.
Phase 1.